COO stock forecast, quote, news & analysis

Key Takeaways

• COO traded near $59 in mid-October 2026, recovering roughly 7% from late September but still well below its pre-earnings level.
• On September 9, 2026, the company beat Q3 adjusted earnings but cut fiscal 2026 guidance and said it would retain CooperSurgical, sending shares down about 15%.
• The primary overhang is CooperVision's U.S. channel inventory reset, which management expects to keep weighing on the fourth quarter.
• Record free cash flow and an expanded $3 billion buyback authorization provided a partial offset to the negative sentiment.
• Activist pressure from Jana Partners and multiple securities investigations add governance and disclosure uncertainty.

Current Market Snapshot

The Cooper Companies (NASDAQ: COO) has been rebuilding from a sharp late-summer decline. After falling roughly 15% in a single session in early September, the stock found support near a 52-week low of $51.01 and has since climbed back toward the high-$50s. The shares remain roughly 20% below year-ago levels and trade near the lower end of a 52-week range that tops out around $89.83.

Sell-side sentiment has cooled in the wake of the guidance reset. Analysts tracked by S&P Global now carry a consensus "Hold" rating with an average 12-month price target near $65, reflecting a cautious but not uniformly bearish posture. With a market capitalization of roughly $11 billion, COO remains one of the larger diversified medical device names in the eyecare and women's health markets.

The Cooper Companies (COO) Business Overview and Competitive Position

Founded in 1958 and headquartered in San Ramon, California, The Cooper Companies operates through two segments. CooperVision, the larger unit, designs and manufactures contact lenses and is one of the world's leading pure-play lens makers, holding a meaningful share of the U.S. market. Its portfolio spans daily disposable silicone hydrogel lenses, the MyDay franchise, and MiSight, a lens approved for slowing myopia progression in children.

CooperSurgical provides medical devices and services for women's health, with a particular focus on fertility. In the most recent quarter, CooperSurgical grew fertility revenue about 5%, supported by genomics and new clinic wins. Investors follow COO for its exposure to structurally growing eyecare and fertility end markets, its recurring revenue model, and its historically strong free cash flow generation.

Recent Developments Driving COO

The defining event of the period was the company's September 9, 2026, fiscal third-quarter report for the quarter ended July 31, 2026. Consolidated revenue rose about 1% to roughly $1.07 billion, while adjusted diluted earnings per share came in at $1.15, ahead of consensus. CooperVision revenue of about $717 million was essentially flat, and CooperSurgical revenue of about $349 million rose modestly.

The negative reaction stemmed from guidance rather than the quarter itself. Management trimmed full-year fiscal 2026 revenue guidance to roughly $4.23 billion to $4.25 billion and adjusted EPS to $4.51 to $4.55, both below the prior outlook and Wall Street estimates. Fourth-quarter adjusted EPS guidance of $1.05 to $1.09 sat well below the roughly $1.19 consensus. Executives attributed the shortfall primarily to a deliberate reduction in U.S. distributor inventory at CooperVision, framed as a reset ahead of fiscal 2027.

Compounding the disappointment, the board concluded a strategic review by deciding to retain CooperSurgical, removing a potential divestiture catalyst that some investors had anticipated. Separately, activist investor Jana Partners issued a public letter calling for a new chief executive and board chair and for an evaluation of asset sales. Several law firms announced investigations into the company's disclosures around demand, inventory, and guidance.

Not all signals were negative. The company posted record quarterly free cash flow of about $273 million, raised its share repurchase authorization from $2 billion to $3 billion, and reported a one-time tax benefit of roughly $307 million. Director Lawrence Kurzius also purchased about 10,000 shares in mid-September, a move some read as a vote of confidence in a turnaround.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform that offers hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently attracting attention. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon trend systems. This variety allows users to compare different methodologies rather than relying on a single signal. For investors interested in data-driven tools to complement their own research, exploring the Trending AI Robots section can provide a useful starting point.

2026 Outlook and What Investors Should Watch

Several factors will shape COO's trajectory through the remainder of the fiscal year and into 2027. The most immediate is the company's fourth-quarter report, which will reveal whether the CooperVision inventory reset stays contained to a single quarter or extends further. Management has guided to flat-to-low-single-digit organic growth for the period, and the market will be watching whether underlying consumption, rather than channel shipments, supports a reacceleration in fiscal 2027.

Other items to monitor include an expected increase in the non-GAAP effective tax rate to roughly 17.5% in fiscal 2027, ongoing currency pressure, and the level of commercial investment needed to restore growth. At CooperSurgical, fertility demand, a new entrant in the non-hormonal IUD market, and fertility-related litigation settlements will influence sentiment. Finally, the activist campaign and any resulting changes to leadership, board structure, or capital allocation could affect the stock's direction, alongside the pace and scale of share repurchases under the expanded authorization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations